At least for us, the ESC Congress 2015 in London was different from the previous ones as we did not organize Satellite Symposium on rare cardiovascular diseases. It is not that we did not want to, on the contrary we tried as much as we could, but due to the fact that our EU Project MRPO 08.02.00-12-424/10 has eventually came to an end we did not possess adequate financial back-up to organize the session. Certainly, this is not good news for all somehow accustomed to our annual session, but on the other hand the light we torched some time ago has not been extinguished. During numerous informal meetings at the Congress we tried to cultivate what we had jointly started some time ago. As in real life, there are ups and downs and it is not difficult to carry on when everything clicks into place but real challenge is to survive even in the dark days. But now a little about the Congress itself.

The London Congress hosted record number of more than 32,000 participants. There were record number of late-breaking science presentations that include 28 clinical Hot Lines, 18 Clinical Trial Updates, 20 registry studies, 12 basic and translational science Hot Line studies and 4533 abstract studies. Moreover, five new Practice Guidelines on Acute Coronary Syndromes-NSTE, Ventricular Arrhythmias and Sudden Cardiac Death, Pulmonary Hypertension, Infective Endocarditis and Pericardial Diseases were launched during the Congress. Finally, the audience was inspired with the presence of Nobel Prize Laurate Elizabeth Blackburne. She was awarded the 2009 Nobel Prize in Physiology and Medicine for discovering molecular nature of telomeres (the ends of eukaryotic chromosomes that serve as protective caps) and the enzyme telomerase. Undoubtedly there is a link between length of telomere and various cardiovascular diseases. This only speaks for itself.

Environment and the heart was the spotlight of the Congress. There is growing body of evidence that links air pollution and cardiovascular diseases. Unless we seriously tackle this problem, it is estimated that by 2050 urban air pollution will be the top environmental cause of mortality worldwide.

To present the real scientific content of the Congress is certainly beyond the scope of this report. However, there are several landmark trails that cannot pass unnoticed. Professor Martin Cowie, from the Imperial Collage of London, presented disappointing results of the SERVE-HF study that found the device known as adaptive servo-ventilation (ASV) therapy increase mortality in heart failure patients with central sleep apnea. The results of this study came as a bucket of icy water for all HF community as previous small studies suggested multiple benefits of ASV. The SERVE-HF is a perfect example of the pivotal role of randomized controlled trails in contemporary medicine. Another study that has a potential to change the landscape of cardiology is the LEADLESS II that demonstrated good safety and reliable function of leadless pacemakers. It is still too early but far on the horizons is looming the prospect of default leadless pacemakers in majority of patients. For all those who lost hope in the treatment of resistant hypertension, the encouraging news come from the PATHWAY-2 study that showed that an “old” drug – Spironolactone was three times more effective than Doxazosine and Bisoprolol to exert control in resistant hypertension. The successful path of angiotensin receptor inhibitor/neprilysin inhibitor of valsartan/sacubitril, that has already proved efficiency in heart failure in the last year landmark trail of PARDIGM-HF, continues. The combined drug, known now as ARNI, has shown its efficacy in the treatment of systolic hypertension in the elderly. Perhaps exotic in Europe but Chagas cardiomyopathy is enormous problem in Latin and South America with more than 7 million patients affected. The BENEFIT study was the largest to examine the effect of Benzimidazole in cardiomyopathy patients with Chagas disease that is caused by parasitic infection of Trypanosomiasis cruzi. Although the prolonged treatment with Benzimidazole did not reduce the progression of cardiomyopathy but significantly reduced parasitic activity in the blood. This short report gives just a glimpse of the real scientific content of the Congress that can be easily accessed via official ESC website.

Figure 1. Doctor Piotr Musialek in front of his abstract just before presentation
Finally, just few words about our own scientific activities. Despite the fact that we did not have own session we were involved in several sessions in which we presented results of our studies on rare cardiovascular disease. Doctor Monika Komar presented results on various aspects of percutaneous management of patients with atrial septal defect and patent foramen ovale during four poster sessions. Importantly, one of her abstract entitled "Improvement of exercise capacity after transcatheter closure of atrial septal defect is impacted by the tricuspid insufficiency" was presented during Best Poster session in congenital heart disease. Doctor Piotr Musialek presented his study on fibrin clot properties in patients with atherosclerotic carotid artery stenosis during poster session dedicated to carotid disease. The other representative from the Krakow Center for Rare Cardiovascular Diseases – dr Pawel Rubis presented the results of the study entitled "Comparison of two models estimating sudden cardiac death risk in hypertrophic cardiomyopathy. Impact on primary prevention practice" during Rapid Fire session on Hot issues in cardiomyopathies.

The annual ESC Congress 2015 in London was a great success not only for the organizers but also for every participant who "laid a small brick". Now is the time to study in detail the rich scientific content that is widely available. At least some of the incoming long autumn evenings shall be spend with printed Congress reports or downloaded article on your laptop. As you wish!
Aims and scope
Journal of Rare Cardiovascular Diseases (JRCD) is an international, quarterly, peer reviewed journal that keeps cardiologists up to date with rare disorders of heart and vessels. Topics covered include congenital heart defects, cardiomyopathies, rhythm abnormalities, rare forms of arterial hypertension, pulmonary hypertension, cardiac tumors and other rare diseases affecting heart and vessels such as connective tissue diseases, metabolic disorders, neuro-muscular diseases another unclassified rare diseases.

Instructions for authors
The Journal will consider for publication articles written in English.

Types of papers
The following types of papers will be considered for publication in JRCD:
Original articles: word limit 4000 words, 40 references, no more than 6 figures/tables
Review articles: word limit 5000 words, 50 references, no more than 5 figures
Brief Report: word limit 2000 words, 20 references, no more than 4 figures
Case Report: word limit 3500 words, 30 references, no more than 5 figures.
Letters to editor: up to 600 words

Editorial
The type of paper should be indicated on the title page.

Manuscript submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission
All articles must be submitted using an electronic submission system at: www.jrcd.eu.

Title page
The title page should include:
- Type of paper
- The name(s) of the author(s)
- A concise and informative title
- The affiliation(s) and address(es) of the author(s)
- The e-mail address, telephone and fax numbers of the corresponding author
- Declaration of conflict of interest

Abstract
Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.

Keywords
Please provide 4 to 6 keywords which can be used for indexing purposes.

Text
Text Formatting
Manuscripts should be submitted in Word. Use a normal, plain font (e.g., 12-point Times Roman) for text. Use italics for emphasis. Use the automatic page numbering function to number the pages. Do not use field functions. Use tab stops or other commands for indents, not the space bar. Use the table function, not spreadsheets, to make tables. Use the equation editor or MathType for equations. Save your file in doc format. Do not submit docx files.

Headings
Please use no more than three levels of displayed headings. Original article should consists of the following sections: Background, Methods, Results, Discussion, Conclusions, References. Case reports should include the following headings: Case presentation, Review of literature, Patient management and follow-up, References.

Abbreviations
Abbreviations should be defined at first mention and used consistently thereafter.

Footnotes
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables. Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full.

Scientific style Please always use internationally accepted signs and symbols for units (SI units).

Generic names of drugs are preferred; if trade names are used, the generic name should be given at first mention.

References
Reference citations in the text should be identified by numbers in square brackets [].
The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.
The entries in the list should be numbered consecutively.
Please, list the first three authors and add “et al.”.

Tables
All tables are to be numbered using Arabic numerals.
Tables should always be cited in text in consecutive numerical order.
For each table, please supply a table caption (title) explaining the components of the table.
Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
Footnotes to tables should be indicated by superscript lower-case letters and included beneath the table body.

Artwork / Figure
For the best quality final product, it is highly recommended that you submit all of your artwork – photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the highest standards with the greatest accuracy to detail. The published work will directly reflect the quality of the artwork provided.
Supply all figures electronically.
Indicate what graphics program was used to create the artwork.

Figure Numbering
All figures are to be numbered using Arabic numerals.
Figures should always be cited in text in consecutive numerical order.
Figure parts should be denoted by lowercase letters (a, b, c, etc.). Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Permissions
If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Publisher will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

Electronic Supplementary Material
We accept electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online. This feature can add dimension to the author’s article.
Supply all supplementary material in standard file formats. Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.
For each supplementary material, please supply a concise caption describing the content of the file.

Ethical standards
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements.

Conflict of interest
Authors must indicate whether or not they have a financial relationship with the organization that sponsored the research. They should also state that they have full control of all primary data and that they agree to allow the journal to review their data if requested.
Therefore the manuscript must be accompanied by the “Conflict of Interest Disclosure Form”. To download this form, please follow the hyperlink on the right.

Copyright transfer
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.

Disclaimer
The authors, editors and publisher will not accept any legal responsibility for any errors or omissions that may be made in this publication.
The publisher makes no warranty, express or implied, with respect to the material contained herein.